PA
VIR icon

Perceptive Advisors’s Vir Biotechnology VIR Stock Holding History

Perceptive Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,958,264
Closed -$48M – 104
2023
Q2 		$48M Buy
1,958,264
+1,816,070
+1,277% +$45.6M 1.39% 19
2023
Q1 		$3.31M Buy
+142,194
New +$3.64M 0.1% 83
2020
Q3 		– Sell
-13,024
Closed -$534K – 142
2020
Q2 		$534K Buy
+13,024
New +$437K 0.01% 122

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors's VIR Position: Q3 2023 in Review

Perceptive Advisors sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 1,958,264 shares — an estimated $48M sold.

Perceptive Advisors first reported a position in VIR in Q2 2020 and held it in 3 quarters. The position peaked at $48M in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Perceptive Advisors reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Perceptive Advisors sold 1,958,264 Vir Biotechnology shares in Q3 2023, an estimated $48M.
  • Perceptive Advisors first reported a position in Vir Biotechnology in Q2 2020 and held it in 3 quarters.
  • Perceptive Advisors's Vir Biotechnology position peaked at $48M in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.